PSMB9 and neoplasm: The optimized HLA A*1101-restricted TCR led to the generation of high-avidity T cells with strong antigen-specific functions, such as proliferation, cytotoxicity, and cytokine release. These engineered T cells effectively inhibited LMP2-positive tumour growth in a mouse model and lysed LMP2-expressing NPC cells from advanced NPC patients.